The global ovarian cancer diagnostics market size is likely to be valued at US$1.9 billion in 2026, and is expected to reach US$3.1 billion by 2033, growing at a CAGR of 7.1% during the forecast period from 2026 to 2033, driven by the increasing clinical emphasis on early detection, as ovarian cancer is frequently diagnosed at advanced stages due to its nonspecific symptoms. The significant improvement in patient outcomes associated with early-stage diagnosis continues to strengthen demand for advanced diagnostic technologies, positioning ovarian cancer diagnostics as a critical segment within gynecological oncology.

Driver - Rising Global Ovarian Cancer Incidence and the Hereditary BRCA Screening Imperative

The American Cancer Society estimates approximately 19,680 new ovarian cancer diagnoses and 12,740 deaths in the U.S. in 2024, reflecting the disease’s sustained epidemiological burden despite therapeutic advances. Critically, approximately 10-15% of all epithelial ovarian cancer cases are attributable to germline BRCA1 or BRCA2 mutations, creating a hereditary cancer screening imperative that extends diagnostic testing demand beyond diagnosed patients to their first- and second-degree relatives through cascade genetic testing programs.

The National Comprehensive Cancer Network (NCCN) guidelines recommend BRCA1/2 testing for all women diagnosed with high-grade epithelial ovarian cancer regardless of family history or age at diagnosis, and recommend cascade testing for BRCA-positive patients’ relatives, creating an expanding testing population that includes not only patients but their families. The Society of Gynecologic Oncology (SGO) and ACOG have issued consistent guidance supporting universal BRCA genetic testing in epithelial ovarian cancer patients, driving testing volume growth through systematic clinical guideline implementation across U.S. and European gynecologic oncology practices.

Restraint - Absence of a Validated Ovarian Cancer Population Screening Test

Unlike breast cancer (mammography) and cervical cancer (Pap smear/HPV testing), no validated population-level screening test for ovarian cancer exists for average-risk women, representing the most fundamental barrier to market expansion beyond the diagnosed patient and hereditary high-risk testing populations. The U.K. Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), the world’s largest ovarian cancer screening randomized trial enrolling 202,638 women, published its final results in The Lancet in 2021, demonstrating that multimodal screening with serial CA-125 using the Risk of Ovarian Cancer.

The U.S. Preventive Services Task Force (USPSTF) maintains a Grade D recommendation against ovarian cancer screening in average-risk women, actively discouraging CA-125 and transvaginal ultrasound screening outside clinical trial settings, limiting the addressable screening market to hereditary high-risk women identified through BRCA and Lynch syndrome genetic testing programs.

Opportunity - AI-Enhanced Transvaginal Ultrasound and Radiomics for Adnexal Mass Characterization

Transvaginal ultrasound (TVUS) remains the primary imaging modality for initial adnexal mass evaluation in women presenting with pelvic symptoms or elevated CA-125, but its diagnostic accuracy for distinguishing benign from malignant ovarian masses is highly operator-dependent and exhibits significant inter-observer variability in morphological feature interpretation. The integration of artificial intelligence and radiomics into TVUS image analysis represents a high-impact opportunity to standardize and enhance the diagnostic accuracy of ovarian mass characterization, enabling consistent application of validated classification criteria including IOTA (International Ovarian Tumour Analysis) Simple Rules and O-RADS (Ovarian-Adnexal Reporting and Data System) across clinical settings with variable ultrasonographer expertise.

GE HealthCare’s AI-enhanced gynecological imaging systems are among the leading commercial implementations of AI-assisted adnexal imaging, with clinical validation studies demonstrating AI-augmented TVUS achieving specificity improvements of 10-15 percentage points in malignancy classification compared with conventional operator-dependent assessment, reducing unnecessary surgical referrals for benign masses and improving malignancy detection rates in community gynecology settings that lack specialized gynecologic oncology sonography expertise.

Cancer Type Insights

Epithelial tumors are expected to dominate the cancer type segment, commanding approximately 88% of total revenue in 2026, due to their high prevalence. Their high prevalence drives strong demand for diagnostic tools, including biomarker assays, molecular testing, and genetic profiling, to enable early and accurate diagnosis. Their large patient population drives substantial demand for diagnostic testing, targeted therapies, and ongoing disease monitoring. Advances in molecular profiling and precision oncology have further increased spending on epithelial tumor management.

Germ cell tumors are likely to be the fastest-growing cancer type segment, driven by rising incidence in younger women, growing awareness of tumor marker panels including AFP (alpha-fetoprotein), hCG (β-human chorionic gonadotropin), and LDH for germ cell tumor diagnosis and monitoring, and expanding pediatric and adolescent gynecologic oncology programs deploying specialized germ cell tumor diagnostic protocols at academic cancer centers in North America and Europe.

Diagnosis Insights

Blood tests are projected to account for approximately 42% of the global ovarian cancer diagnostics market revenue in 2026, making them the leading diagnostic modality. Their dominance is attributed to their widespread use as a first-line diagnostic approach, offering a minimally invasive, cost-effective, and rapid means of detecting disease-associated biomarkers. The increasing adoption of advanced blood-based technologies, including liquid biopsy and molecular diagnostic assays, is further enhancing their clinical value and supporting segment growth.

Biopsy is likely to be the fastest-growing diagnostic modality, driven by the growing clinical adoption of liquid biopsy for ctDNA-based BRCA somatic mutation detection as a complement to tissue biopsy in recurrent ovarian cancer, the expanding requirement for comprehensive tumor molecular profiling including HRD scoring and broad HRR gene panel testing that requires tumor tissue or ctDNA as the analytical substrate, and the development of minimally invasive laparoscopic biopsy techniques replacing open surgical staging in select clinical scenarios.

End-user Insights

Hospital laboratories are anticipated to lead the end-user segment, holding approximately 48% of the total revenue in 2026. Academic medical centers and comprehensive cancer center hospital laboratories are the primary sites for ovarian cancer staging biopsy analysis, immunohistochemistry-based tumor subtype classification, CA-125 and HE4 immunoassay, and in-house or referral-based BRCA and HRR molecular testing services.

Cancer diagnostic centers are likely to be the fastest-growing end-user segment, driven by the shift of specialized molecular ovarian cancer diagnostic services including comprehensive genomic profiling, HRD testing, and ctDNA liquid biopsy to dedicated cancer diagnostic reference laboratories including Foundation Medicine, Quest Diagnostics Oncology, and Caris Life Sciences, which offer superior turnaround times, specialized bioinformatics interpretation, and clinically integrated molecular tumor board reporting that most hospital laboratories cannot match in-house.

North America Ovarian Cancer Diagnostics Market Trends

North America market growth is projected to dominate, holding approximately 40% revenue share in 2026. The region’s leadership reflects the highest concentration of PARP inhibitor companion diagnostic testing volume, the world’s most comprehensive BRCA hereditary testing infrastructure, and FDA-driven companion diagnostic approval requirements creating mandatory testing events across the ovarian cancer treatment pathway.

U.S. Ovarian Cancer Diagnostics Market Trends

The U.S. is expected to account for approximately 89% of North America revenue in 2026. The American Cancer Society’s 2024 data documenting approximately 19,680 new U.S. ovarian cancer diagnoses represents the core annual incident testing population, with NCCN’s universal BRCA testing guideline ensuring that each new epithelial ovarian cancer diagnosis generates both a BRCA germline test and a companion diagnostic assessment for PARP inhibitor eligibility.

Canada Ovarian Cancer Diagnostics Market Trends

Canada is estimated to hold approximately 11% of North America revenue in 2026, with provincial cancer program networks implementing BRCA testing protocols aligned with U.S. NCCN guidelines and a growing hereditary cancer genetic counseling infrastructure driving cascade BRCA testing in BRCA-positive patient families.

Europe Ovarian Cancer Diagnostics Market Trends

Europe is forecast to hold approximately 28% of global revenue in 2026, and is projected to grow at a CAGR of approximately 10.6% from 2026 to 2033. Europe’s well-established oncology diagnostic infrastructure, EMA companion diagnostic co-approval framework, and national hereditary cancer genetic testing programs create a structurally favorable environment for ovarian cancer diagnostics market development.

Germany Ovarian Cancer Diagnostics Market Trends

Germany market is expected to command approximately 23% of the regional market revenue in 2026, driven by the German gynecologic oncology community’s systematic implementation of BRCA testing in all newly diagnosed ovarian cancer patients, GlaxoSmithKline’s niraparib (Zejula) commercial launch generating myChoice CDx HRD testing volume across German oncology centers, and Siemens Healthcare GmbH’s domestic CA-125 and HE4 immunoassay platform presence in German hospital laboratories.

U.K. Ovarian Cancer Diagnostics Market Trends

The U.K. is estimated to hold approximately 21% of the regional market share in 2026, with NHS England’s cancer genomics program implementing BRCA germline testing through its Genomics Laboratory Hub network and NICE approval of olaparib, niraparib, and rucaparib for ovarian cancer generating companion diagnostic testing demand across NHS gynecological oncology services.

Asia Pacific Ovarian Cancer Diagnostics Market Trends

Asia Pacific is projected to be the fastest-growing regional market, expanding at a CAGR of approximately 12.8% during the forecast period from 2026 to 2033. Growth is driven by the region's large ovarian cancer patient population, rising prevalence of associated risk factors, and improving access to diagnostic services. According to GLOBOCAN 2022, Asia accounted for approximately 57% of global ovarian cancer cases, reflecting its significant disease burden. Despite this high incidence, diagnostic penetration remains comparatively low, creating substantial opportunities for the adoption of advanced ovarian cancer diagnostic technologies across the region.

China Ovarian Cancer Diagnostics Market Trends

China is projected to account for approximately 35% of the Asia Pacific ovarian cancer diagnostics market in 2026, supported by its large patient population and expanding precision oncology infrastructure. According to GLOBOCAN 2022, China records approximately 61,100 new ovarian cancer cases annually, representing the largest disease burden globally. The approval of targeted therapies such as olaparib and niraparib by the National Medical Products Administration (NMPA) has accelerated demand for BRCA and homologous recombination deficiency (HRD) companion diagnostic testing.

In addition, the continued expansion of next-generation sequencing (NGS) capabilities across leading oncology centers is driving broader adoption of molecular diagnostics throughout the country.

Japan Ovarian Cancer Diagnostics Market Trends

Japan is projected to account for approximately 22% of the Asia Pacific ovarian cancer diagnostics market in 2026, supported by its well-established oncology care infrastructure and strong emphasis on precision medicine. The approval of targeted therapies such as olaparib and niraparib by the Pharmaceuticals and Medical Devices Agency (PMDA) has increased the need for companion diagnostic testing, particularly for BRCA mutations, in line with clinical practices adopted in the U.S. and Europe.

Furthermore, the Japan Society of Obstetrics and Gynecology (JSOG) recommends BRCA testing for all patients with epithelial ovarian cancer, further driving the adoption of molecular diagnostic technologies.

The global ovarian cancer diagnostics market features a competitive landscape defined by global pharmaceutical-diagnostics conglomerates with integrated companion diagnostic programs, specialized molecular oncology diagnostics companies, and immunoassay platform manufacturers serving the CA-125 and HE4 surveillance testing market.

AstraZeneca, as olaparib’s developer, maintains deep commercial alignment with companion diagnostic partners including Roche and Myriad Genetics, with its PAOLA-1 trial incorporating myChoice CDx HRD testing as the companion diagnostic for first-line olaparib plus bevacizumab treatment selection, demonstrating the pharma-diagnostics co-development model that is the primary driver of structured companion diagnostic demand in ovarian cancer.

Key Industry Developments:

• In March 2025, Komodo Health partnered with Ovarian Cancer Research Alliance to publish data highlighting disparities in ovarian cancer diagnostic testing, which prompted insurers and hospitals to revise guidelines and expand coverage for BRCA and HRD testing.
• In January 2025, the Ovarian Cancer Research Alliance launched a nationwide awareness campaign in the U.S. to increase genetic testing uptake among women, with a particular focus on underserved populations aged over 65 and individuals covered by public insurance.